- Home
- GROV vs CNTB Comparison
GROV vs CNTB Comparison
Compare GROV & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- CNTB
- Stock Information
- Founded
- GROV 2016
- CNTB 2012
- Country
- GROV United States
- CNTB United States
- Employees
- GROV N/A
- CNTB N/A
- Industry
- GROV Package Goods/Cosmetics
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- CNTB Health Care
- Exchange
- GROV Nasdaq
- CNTB Nasdaq
- Market Cap
- GROV 56.5M
- CNTB 65.5M
- IPO Year
- GROV N/A
- CNTB 2021
- Fundamental
- Price
- GROV $1.35
- CNTB $0.99
- Analyst Decision
- GROV Buy
- CNTB Strong Buy
- Analyst Count
- GROV 1
- CNTB 1
- Target Price
- GROV $2.00
- CNTB $8.00
- AVG Volume (30 Days)
- GROV 92.7K
- CNTB 29.3K
- Earning Date
- GROV 11-12-2024
- CNTB 09-05-2024
- Dividend Yield
- GROV N/A
- CNTB N/A
- EPS Growth
- GROV N/A
- CNTB N/A
- EPS
- GROV N/A
- CNTB N/A
- Revenue
- GROV $213,781,000.00
- CNTB $24,116,000.00
- Revenue This Year
- GROV N/A
- CNTB N/A
- Revenue Next Year
- GROV $5.97
- CNTB $63.90
- P/E Ratio
- GROV N/A
- CNTB N/A
- Revenue Growth
- GROV N/A
- CNTB N/A
- 52 Week Low
- GROV $1.19
- CNTB $0.68
- 52 Week High
- GROV $2.44
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- GROV 49.78
- CNTB 39.75
- Support Level
- GROV $1.30
- CNTB $0.91
- Resistance Level
- GROV $1.41
- CNTB $1.09
- Average True Range (ATR)
- GROV 0.09
- CNTB 0.11
- MACD
- GROV -0.00
- CNTB -0.01
- Stochastic Oscillator
- GROV 30.36
- CNTB 16.18
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.